399 related articles for article (PubMed ID: 30617121)
61. Effectiveness of seasonal influenza vaccines against influenza-associated illnesses among US military personnel in 2010-11: a case-control approach.
Eick-Cost AA; Tastad KJ; Guerrero AC; Johns MC; Lee SE; Macintosh VH; Burke RL; Blazes DL; Russell KL; Sanchez JL
PLoS One; 2012; 7(7):e41435. PubMed ID: 22859985
[TBL] [Abstract][Full Text] [Related]
62. Survey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics.
Jacobson SH; Sewell EC; Jokela JA
Expert Rev Vaccines; 2007 Dec; 6(6):981-90. PubMed ID: 18377360
[TBL] [Abstract][Full Text] [Related]
63. T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine.
Schmidt A; Lapuente D
Viruses; 2021 Jan; 13(2):. PubMed ID: 33525620
[TBL] [Abstract][Full Text] [Related]
64. BIOSECURITY. Flu study raises questions about U.S. ban.
Cohen J
Science; 2015 Sep; 349(6253):1153. PubMed ID: 26359382
[No Abstract] [Full Text] [Related]
65. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
[TBL] [Abstract][Full Text] [Related]
66. [Composition of the Belgian influenza vaccines for the 2015-2016 season].
Van Steenkiste M
J Pharm Belg; 2015 Sep; (3):14-23. PubMed ID: 26513832
[TBL] [Abstract][Full Text] [Related]
67. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.
van Doorn E; Liu H; Ben-Yedidia T; Hassin S; Visontai I; Norley S; Frijlink HW; Hak E
Medicine (Baltimore); 2017 Mar; 96(11):e6339. PubMed ID: 28296763
[TBL] [Abstract][Full Text] [Related]
68. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
69. Influenza virus hemagglutinin stalk-based antibodies and vaccines.
Krammer F; Palese P
Curr Opin Virol; 2013 Oct; 3(5):521-30. PubMed ID: 23978327
[TBL] [Abstract][Full Text] [Related]
70. Reverse genetics for influenza B viruses and recent advances in vaccine development.
Cardenas-Garcia S; Caceres CJ; Rajao D; Perez DR
Curr Opin Virol; 2020 Oct; 44():191-202. PubMed ID: 33254031
[TBL] [Abstract][Full Text] [Related]
71. [Seroconversion after vaccine with trivalent influenza vaccine during the epidemic season 1990/1 in Poland].
Brydak L; Rudnicka H; Gut W; Magdzik W; Kańtoch M
Przegl Epidemiol; 1992; 46(3):221-9. PubMed ID: 1296247
[TBL] [Abstract][Full Text] [Related]
72. Physician knowledge and perspectives regarding influenza and influenza vaccination.
Dominguez SR; Daum RS
Hum Vaccin; 2005; 1(2):74-9. PubMed ID: 17038822
[TBL] [Abstract][Full Text] [Related]
73. [Research progress and prospect of universal influenza vaccine].
Luo DY; Xue CY; Cao YC
Bing Du Xue Bao; 2013 Nov; 29(6):646-50. PubMed ID: 24520771
[TBL] [Abstract][Full Text] [Related]
74. Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.
Calzas C; Chevalier C
Front Immunol; 2019; 10():1605. PubMed ID: 31379823
[TBL] [Abstract][Full Text] [Related]
75. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?
Tan J; Asthagiri Arunkumar G; Krammer F
Curr Opin Immunol; 2018 Aug; 53():45-50. PubMed ID: 29677684
[TBL] [Abstract][Full Text] [Related]
76. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting.
Livingston BD; Higgins D; Van Nest G
BioDrugs; 2006; 20(6):335-40. PubMed ID: 17176120
[TBL] [Abstract][Full Text] [Related]
77. Broadly Reactive Influenza Antibodies Are Not Limited by Germinal Center Competition with High-Affinity Antibodies.
Keating R; Johnson JL; Brice DC; Labombarde JG; Dent AL; McGargill MA
mBio; 2020 Nov; 11(6):. PubMed ID: 33144374
[TBL] [Abstract][Full Text] [Related]
78. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022.
Chung JR; Kim SS; Kondor RJ; Smith C; Budd AP; Tartof SY; Florea A; Talbot HK; Grijalva CG; Wernli KJ; Phillips CH; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Reis M; Geffel KM; Nowalk MP; DaSilva J; Keong LM; Stark TJ; Barnes JR; Wentworth DE; Brammer L; Burns E; Fry AM; Patel MM; Flannery B
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):365-370. PubMed ID: 35271561
[TBL] [Abstract][Full Text] [Related]
79. Influenza vaccines: the good, the bad, and the eggs.
Schultz-Cherry S; Jones JC
Adv Virus Res; 2010; 77():63-84. PubMed ID: 20951870
[TBL] [Abstract][Full Text] [Related]
80. Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs.
Harding AT; Heaton BE; Dumm RE; Heaton NS
mBio; 2017 Jun; 8(3):. PubMed ID: 28588131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
